News
-
According to Genoa Pharmaceuticals, a pre-clinical study conducted at McMaster University demonstrated that the company’s GP-101 inhaled pirfenidone demonstrated statistically significant greater anti-fibrotic effect in an in vivo model of pulmonary fibrosisi than did higher… Read more . . .
-
Irish biotech company Elan, which recently paid $1 billion to Theravance for royalty payments from sales of Breo (Relvar) Ellipta and other inhaled drugs, has been awarded an injunction against Royalty Pharma by an Irish… Read more . . .
-
Submit abstracts for posters and podium presentations by July 26, 2013 at http://www.ddl-conference.org.uk/?q=abstractsubmissionDDL24 Full guidelines available at http://www.ddl-conference.org.uk/files2/Abstract_Guidelines_2013.pdf. Read more . . .
-
According to reports, Johnson & Johnson described development of a ketamine nasal spray for the treatment of depression during a meeting with analysts on May 23, 2013. The product is not listed among the company’s… Read more . . .
-
Despite most delegates having partied past midnight at the previous night’s gala dinner, the 8:30 a.m. session on “Designing Devices for the Marketplace” Day 3 of RDD Europe 2013 was very well attended. . .… Read more . . .
-
On Day 2 of RDD Europe 2013, the focus was primarily on regulatory issues. . . . Read more Read more . . .
-
A new consortium described as a “series of conceptual research projects in the area of nasal physiology, function and drug delivery” that “aims to enhance understanding in the area of upper respiratory tract disorders and… Read more . . .
-
On the morning of May 22, one of the organizers of RDD Europe 2013, Peter Byron, opened the meeting by welcoming approximately 470 delegates back to Berlin.. . . Read more Read more . . .
-
A study presented at ATS 2013 found that over 40 percent of uninsured patients treated for COPD at a US clinic did not actually have COPD. Researchers from Northeast Ohio Medical University and Saint Elizabeth… Read more . . .
-
Prosonix has started a Phase 2 safety and dose-ranging study of PSX1002 inhaled glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA), in patients with moderate-to-severe COPD, the company has announced. The suspension formulation of PSX1002 engineered… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland